Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II combination epigenetic and differentiation therapy study in acute myeloid leukemia and high-risk myelodysplastic syndrome
ISRCTN68418952Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jun 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of valproic acid, azacitidine, theophylline and tretinoin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Birmingham. Primary endpoints: Safety of four-drug combination and Hematological response. Started Jun 2006; status: completed.
02
Drugs
valproic acidazacitidinetheophyllinetretinoin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN68418952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68418952.